Trial Profile
A Phase 3 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients Currently Treated With ACEI and/or ARB Therapy
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2015
Price :
$35
*
At a glance
- Drugs PCS 499 (Primary)
- Indications Diabetic nephropathies
- Focus Registrational; Therapeutic Use
- Sponsors Concert Pharmaceuticals
- 05 Nov 2015 According to a Concert Pharmaceuticals media release, the company has reached agreement with the U.S. FDA under a Special Protocol Assessment (SPA) for this trial.
- 04 Aug 2014 New trial record